REVIEWS AND META-ANALYSESAntihypertensive drugs and the risk of cancer: a critical review of available evidence and perspectiveBattistoni, Allegraa; Tocci, Giulianoa,b; Coluccia, Robertab; Burnier, Michelc; Ruilope, Luis M.d; Volpe, Massimoa,bAuthor Information aDepartment of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sapienza University of Rome bIRCCS Neuromed, Pozzilli, Italy cUniversity of Lausanne and Hypertension Research Foundation, St Légier, Switzerland dCardiorenal Translational Laboratory and Hypertension Unit, Institute of Research i+12, Hospital Universitario 12 de Octubre, Madrid, Spain Correspondence to Massimo Volpe, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sapienza University of Rome, Sant’Andrea Hospital, Via di Grottarossa 1035–1039, 00198 Rome, Italy. Tel: +39 0633775979; e-mail: [email protected] Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ALLHAT, Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial; ARB, AT1 blocker; AT2R, angiotensin 2 type II receptor; BCC, basal-cell carcinoma; CCB, calcium channel blocker; CHARM, Candesartan in Heart Failure Assessment of Reduction on Mortality and Morbidity; CVD, cardiovascular disease; NDEA, N-nitroso-diethylamine; NMBA, N-methyl-nitroso-butiryc acid; NMSC, nonmelanoma skin cancer; ONTARGET, Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial; RCT, randomized controlled trials; SCC, squamous cell carcinoma Received 14 November, 2019 Revised 22 December, 2019 Accepted 10 January, 2020 Journal of Hypertension: June 2020 - Volume 38 - Issue 6 - p 1005-1015 doi: 10.1097/HJH.0000000000002379 Buy Metrics Abstract The issue of a potential danger of antihypertensive drugs related to cancer susceptibility is currently generating a major debate in the scientific community, concerns in the public and emphasized interest from the media. The present article is a thorough review of what is known on the various classes of antihypertensive drugs concerning the risk of developing different neoplasms and about the suggested pathophysiological mechanisms, whenever available. The main limitations of evidence derived from studies currently available in this setting are also discussed, high-lightening the need for newly developed approaches to generate more accurate recommendations and informed advice for physicians. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.